TY - JOUR
T1 - A new overgrowth syndrome is due to mutations in RNF125
AU - Tenorio, Jair
AU - Mansilla, Alicia
AU - Valencia, María
AU - Martínez-Glez, Víctor
AU - Romanelli, Valeria
AU - Arias, Pedro
AU - Castrejón, Nerea
AU - Poletta, Fernando
AU - Guillén-Navarro, Encarna
AU - Gordo, Gema
AU - Mansilla, Elena
AU - García-Santiago, F.
AU - González-Casado, Isabel
AU - Vallespín, Elena
AU - Palomares, María
AU - Mori, María A.
AU - Santos-Simarro, Fernando
AU - García-Miñaur, Sixto
AU - Fernández, Luis
AU - Mena, Rocío
AU - Benito-Sanz, Sara
AU - Pozo, Ángela Del
AU - Silla, Juan Carlos
AU - Ibañez, Kristina
AU - López-Granados, Eduardo
AU - Martín-Trujillo, Alex
AU - Montaner, David
AU - Consortium, The S.O.G.R.I.
AU - Heath, Karen E.
AU - Campos-Barros, Ángel
AU - Dopazo, Joaquín
AU - Nevado, Julián
AU - Monk, David
AU - Ruiz-Pérez, Víctor L.
AU - Lapunzina, Pablo
N1 - Publisher Copyright:
© 2014 WILEY PERIODICALS, INC.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Overgrowth syndromes (OGS) are a group of disorders in which all parameters of growth and physical development are above the mean for age and sex. We evaluated a series of 270 families from the Spanish Overgrowth Syndrome Registry with no known OGS. We identified one de novo deletion and three missense mutations in RNF125 in six patients from four families with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycemia, and inflammatory diseases resembling Sjögren syndrome. RNF125 encodes an E3 ubiquitin ligase and is a novel gene of OGS. Our studies of the RNF125 pathway point to upregulation of RIG-I-IPS1-MDA5 and/or disruption of the PI3K-AKT and interferon signaling pathways as the putative final effectors. We have identified four mutations in a novel overgrowth gene, RNF125 (Fig A), in six patients with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycaemia and inflammatory diseases resembling Sjögren syndrome. RNF125 encodes an E3 ubiquitin ligase. Functional characterisation showed that the mutations resulted in a dysregulation of RNF125 mRNA expression (Fig B). Additionally, clear differences in induction and degradation kinetics of RIG-I, a RNF125 target protein, between patients and control fibroblasts were observed (Fig C-E).
AB - Overgrowth syndromes (OGS) are a group of disorders in which all parameters of growth and physical development are above the mean for age and sex. We evaluated a series of 270 families from the Spanish Overgrowth Syndrome Registry with no known OGS. We identified one de novo deletion and three missense mutations in RNF125 in six patients from four families with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycemia, and inflammatory diseases resembling Sjögren syndrome. RNF125 encodes an E3 ubiquitin ligase and is a novel gene of OGS. Our studies of the RNF125 pathway point to upregulation of RIG-I-IPS1-MDA5 and/or disruption of the PI3K-AKT and interferon signaling pathways as the putative final effectors. We have identified four mutations in a novel overgrowth gene, RNF125 (Fig A), in six patients with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycaemia and inflammatory diseases resembling Sjögren syndrome. RNF125 encodes an E3 ubiquitin ligase. Functional characterisation showed that the mutations resulted in a dysregulation of RNF125 mRNA expression (Fig B). Additionally, clear differences in induction and degradation kinetics of RIG-I, a RNF125 target protein, between patients and control fibroblasts were observed (Fig C-E).
KW - Autoimmune disorder
KW - Intellectual disability
KW - Macrocephaly
KW - Overgrowth
KW - RNF125
UR - https://www.scopus.com/pages/publications/84911395758
U2 - 10.1002/humu.22689
DO - 10.1002/humu.22689
M3 - Article
C2 - 25196541
AN - SCOPUS:84911395758
SN - 1059-7794
VL - 35
SP - 1436
EP - 1441
JO - Human mutation
JF - Human mutation
IS - 12
ER -